NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE was delisted on the 10th of May, 2024.
40 hedge funds and large institutions have $10.7M invested in NeuBase Therapeutics, Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 6 reducing their positions, and 6 closing their positions.
222% more capital invested
Capital invested by funds: $3.34M → $10.7M (+$7.39M)
100% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 6
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
5% more funds holding
Funds holding: 38 → 40 (+2)
4% less call options, than puts
Call options by funds: $140K | Put options by funds: $146K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$486K |
| 2 |
Renaissance Technologies
New York
|
+$253K |
| 3 |
WS
Wedbush Securities
Los Angeles,
California
|
+$223K |
| 4 |
CC
Cannell & Co
New York
|
+$192K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$81.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$110K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$25.1K |
| 3 |
VF
Virtu Financial
New York
|
-$24K |
| 4 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
-$19.3K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$18K |
NBSE Hedge Fund Activity: Q4 2017 in Review
40 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q4 2017, worth a combined $10.7M — up 222% from $3.34M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new NBSE positions and 6 closed out — a net gain of 2 holders — while 12 added to existing stakes and 6 trimmed.
The largest buyer was Vanguard Group, adding an estimated $486K. The largest seller was Sabby Management, exiting entirely with an estimated $110K sold.
- 40 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q4 2017, up from 38 in Q3 2017.
- Funds reported $10.7M of NeuBase Therapeutics, Inc. Common Stock stock for Q4 2017, up 222% quarter-over-quarter.
- 8 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q4 2017 and 6 closed out, a net change of +2 holders.
- The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q4 2017 was Vanguard Group, an estimated $486K added.
- The largest NeuBase Therapeutics, Inc. Common Stock seller in Q4 2017 was Sabby Management, an estimated $110K sold.
Based on aggregated 13F filings for Q4 2017.